Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

CSL benefits from strength across its business, acquisitions and shareholder-friendly policies. Rising costs and expenses may hurt its profitability.

Hologic's business diversification holds strong potential internationally. Also, its discounted valuation makes it attractive from an investment...

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Efforts to augment its tower business and fiber and small cells are likely to aid CCI despite industry consolidation and high interest rates.

VIRT is expected to benefit from improved trading income and expanding execution services business.

VIRT is expected to benefit from improved trading income and expanding execution services business.

Rising healthcare spending and aging population aid Ventas' senior housing operating portfolio. However, tenant concentration and high interest rates...